Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mark S. Eisman"'
Autor:
Keith Mikule, Paul Lyne, Steven L. Kazmirski, Michelle Lamb, Nancy Su, Qing Ye, Mark Sylvester, Bo Peng, Jeffrey W. Johannes, Chungang Gu, Mark S. Eisman, Wenxian Wang, Rane A. Harrison, Haiqing Hu, Scott David, Xiaolan Zheng
Publikováno v:
Bioorganicmedicinal chemistry letters. 26(19)
During the lead generation and optimization of PARP inhibitors blocking centrosome clustering, it was discovered that increasing hydrogen bond acceptor (HBA) strength improved cellular potency but led to elevated Caco2 and MDR1 efflux and thus poor o
Autor:
Mark S. Eisman, Jennifer L. Werkheiser, Donna L. Maier, Min Ding, Simon Sydserff, A.J. Williams, Jeffrey S. Smith, S.J. Hubbs, D. Perry, Ladislav Mrzljak
Publikováno v:
Neuroscience. 186
Αlpha-7 neuronal nicotinic receptors (NNRs) are considered targets for cognitive enhancement in schizophrenia and Alzheimer's disease. AZD0328 is an alpha-7 NNR partial agonist that enhances cognition in rodents and nonhuman primates at sub-microgra
Autor:
Charles S. Elmore, Geraldine Hill, David Gurley, John C. Gordon, Russell Bialecki, Emily Einstein, Jeffrey S. Smith, David Tuke, Min Ding, Jennifer L. Werkheiser, Mark S. Eisman, Donna L. Maier, Mary J. Bock
Publikováno v:
Neuropharmacology. 61(1-2)
The alpha-7 neuronal nicotinic receptor is a novel pharmacological target for psychiatric and cognitive disorders. Selective radiotracer tools for pre-clinical receptor occupancy can facilitate the interpretation of the biological actions of small mo
Autor:
Stephen H. Curry, Nik A. Mahmood, Dennis J. McCARTHY, Mark S. Eisman, Ken R. Case, Matthew R. Marler
Publikováno v:
Annals of the New York Academy of Sciences. 765
Autor:
James J. Napier, George E. Garske, Metro Fedorchuk, Robert J. Murray, Ronald C. Griffith, Ranjit Ray, Mark S. Eisman, Mary L. Stagnitto, Theresa C.M. Wilson, Gene C. Palmer
Publikováno v:
Epilepsy research. 12(1)
Remacemide hydrochloride ((±)-2-amino-N-(1-methyl-1,2-diphenylethyl)-acetamide hydrochloride or FPL 12924AA) is a novel compound undergoing clinical trials for patients with generalized tonic/clonic and complex partial epilepsy. Remacemide exhibits
Autor:
CURRY, STEPHEN, McCARTHY, DENNIS J., CASE, KEN R., EISMAN, MARK S., MARLER, MATTHEW R., MAHMOOD, NIK A.
Publikováno v:
Annals of the New York Academy of Sciences; 1995, Vol. 765 Issue 1, p330-331, 2p